Liposomal cytarabine for leukemic and lymphomatous meningitis: Recent developments

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 2, 2008, Pages 301-309

  Benesch, Martin ^a   Urban, Christian ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

CNS prophylaxis; Liposomal cytarabine; Lymphomatous meningjtis; Neurotoxicity; Side effect

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; LIPOSOME; METHOTREXATE; THIOTEPA; VINCRISTINE;

ARACHNOIDITIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN INFARCTION; BRAIN PSEUDOTUMOR; CANCER CHEMOTHERAPY; CAUDA EQUINA SYNDROME; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFUSION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LEUKEMIA; LEUKEMIC MENINGITIS; LYMPHOMA; LYMPHOMATOUS MENINGITIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NONHUMAN; SINGLE DRUG DOSE; SOMNOLENCE; SUSTAINED RELEASE FORMULATION;

ANIMALS; CYTARABINE; HUMANS; LEUKEMIA; LIPOSOMES; LYMPHOMA; MENINGITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 39049158179     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.2.301     Document Type: Article

References (63)

1. Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006;107:473-9
2. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006;108:465-72
3. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000;95:3310-22
4. Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006;108:1165-73
5. Moghrabi A, Lewy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896-904
6. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944-50
7. Einsiedel HG, von Stackelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87. J Clin Oncol 2005;23:7942-50
8. Camera A, Annino L, Chiurazzi F, et al. GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 2004;89:145-53
9. Nguyen S, Leblanc T, Fenaux P, et al. A white cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002;99:3517-23
10. Castagnola C, Nozza A, Corso A, Bernasconi C. The value of combination thempy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997;82:577-80
11. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092-9
12. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985;65:1071-8
13. Davies JK, Taussig DC, Oakervee H, et al. Long-term follow-up after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia/myelodysplastic syndrome: late CNS relapses despite graft-versus-host disease. J Clin Oncol 2006;24:e23-5
14. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005;19:2030-42
15. Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia 2003;17:2090-6
16. Smith FO, Alonzo TA, Gerbing RB, et al. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005;19:2054-62
17. Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149-57
18. Salzburg J, Burkhardt B, Zimmermann M, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Bedin-Frankfurt-Münster Group report. J Clin Oncol 2007;25:3915-22
19. Hedge U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005;105:496-502
20. Bromberg JE, Breems DA, Kraan J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007;68:1674-9
21. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 2005;44:1-31
22. McMillan A. Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol 2005;131:13-21
23. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003;21:1798-809
24. Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol 2005;75:71-83
25. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Am Soc Hematol Educ Program 2006;142-6
26. Gleissner B, Chamberlain M. Neoplastic meningitis. Lancet Neurol 2006;5:443-52
27. Johnson SA. Nucleoside analogues in the treatment of haematological malignancies. Expert Opin Pharmacother 2001;2:929-43
28. Zimm S, Collins JM, Miser J, et al. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 1984;35:826-30
29. Kobayashi T, Kataoka T, Tsukagoshi S, Sakurai Y. Enhancement of anti-tumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes. Int J Cancer 1977;20:581-7
30. Rustum YM, Dave C, Mayhew E, Papahadjopoulos D. Role of liposome type and route of administration in the antitumor activity of liposome-entrapped 1-β-D-arabinofuranosylcytosine against mouse L1210 leukemia. Cancer Res 1979;39:1390-5
31. Kim S, Kim DJ, Geyer MA, Howell SB. Multivesicular liposomes containing 1-β-D-arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Res 1987;47:3935-7
32. Howell SB. Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoam™ technology. Cancer J 2001;7:219-27
33. Chamberlain MC, Khatibi S, Kim JC, et al. Treatment of leptomeningeal metastasis with intraventricular dministration of depot cytarabine (DTC 101). Arch Neurol 1993;50:261-4
34. Chamberlain MC, Kormanik P, Howell SB, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995;52:912-7
35. Bomgaars L, Geyer JR, Franklin J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004;22:3916-21
36. http://www.fda/gov/cder/foi/nda/99/21-041_DepoCyt_Approv.pdf
37. EMEA/H/C/317; http://www.emea.europa.eu/humandocs/PDFs/EPAR/depocyte/ 126901en1.pdf
38. McClune B, Buadi FK, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 2007;48:1849-51
39. Neumeister PN, Pfeilst_docker M, Linkesch W, Rohn A. Safety and tolerability of intrathecal liposomal cytarabine as CNS prophylaxis in patients with acute lymphoblastic leukemia (ALL). Haematologica 2007;92(s1):8 (#23)
40. Anaclerico B, Bongarzoni V, Chierichini A, et al. Liposomal cytarabine in the central nervous system (CNS) prophylaxis of elderly patients with aggressive B-cell non-Hodgkin's lymphoma (NHL) and undifferentiated acute leukemia (AUL): preliminary results of a single-center experience. Blood 2006;108(Suppl):247b (Abstract 4663)
41. Sancho JM, Deben G, Parker A, et al. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Int J Haematol 2007;86:33-6
42. Brion A, Helias P, Daguindau E, et al. Efficacy and safety of intrathecal depocyte (liposomal cytarabine) in patients with primary CNS lymphoma (PCNSL) or leukaemic meningitis associated with acute leukaemias: a single institution experience in France. Haematologica 2007;92(s1):274 (Abstract 736)
43. Shapiro WR, Schmid R, Glantz M, Miller JJ. A randomized Phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. J Clin Oncol 2006;24(Suppl 18S):1528
44. Sancho JM, Ribera JM, Romero MJ, et al. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica 2006;ECR02
45. Rossi D, Annino L, Bongarzoni V, et al. Efficacy and tolerability of liposomal cytosine arabinoside (DepoCyte®) for the treatment of lymphomatous and leukemic meningitis. Blood 2006;108(Suppl):250b (Abstract 4674)
46. García-Marco JA, Navarro B, Ruiz Sanz E, et al. Efficacy and safety of DepoCyte® (liposomal cytarabine) in patients with CNS involvement from Non-Hodgkin's lymphoma (NHL): a report on 32 patients treated in Spain. Blood 2006;108(Suppl):694a (Abstract 2451)
47. Cascavilla N, Bodenizza C, Carella AM, et al. Use of intrathecal liposomal cytarabine (DepoCyte) as treatment of lymphomatous meningitis. Blood 2006;108(Suppl):251b (Abstract 4677)
48. Sancho JM, Giraldo P, Romero MJ, et al. Compassionate use of intrathecal depot cytarabine (DepoCyte®) in central nervous system (CNS) involvement in acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma in Spain: report of 10 cases. Blood 2006;108(Suppl):209b (Abstract 4518)
49. Camera A, Cerciello G, Perna F, et al. Liposomal cytarabine (Depocyte®) for the treatment of meningeal or CNS disease in acute leukemias (AL) and non-Hodgkin lymphomas (NHL: a single centre experiente. Blood 2006;108(Suppl):214b (Abstract 4540)
50. Björgvinsdóttir H, Heldrup J, Békássy AN, Toporski J. Intrathecal liposomal cytarabine: clinical experience in pediatric leukemia and neuroblastoma patients. Pediatr Blood Cancer 2006; 47(Suppl 4):444
51. Goekbuget N, Bassan R, Hug S, et al. First promising results from an European trail with liposomal cytarabine (Depocyte®) for intrathecal (i.th.) application in CNS relapse acute lymphoblastic leukemia (ALL) or aggressive lymphoma (vaNHL). Onkologie 2005;28(Suppl 3):787
52. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17:3110-6
53. Glantz MJ, Chamberlain MC, Batchelor T, et al. Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. J Clin Oncol 2006;24(Suppl 18S):1530
54. Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;109:3214-8
55. Benesch M, Sovinz P, Krammer B, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007;29:222-6
56. Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007;110:1698
57. Thomas DA, Jabbour E, Kantarjian H, O'Brien S. Neurologic toxicity of intrathecal liposomal cytarabine when used for CNS prophylaxis in conjunction with the hyper-CVAD regimen. Blood 2007;110:1698-9
58. Pui CH. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 2007;48:1672-3
59. Resar LM, Phillips PC, Kastan MB, et al. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1991;71:117-23
60. Schiller G, Gajewski J, Territo M, et al. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992;80:2977-82
61. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents (first of two parts). N Engl J Med 1974;291:75-81
62. Liposomal cytarabine: new drug. Lymphomatous meningitis: no better than standard cytarabine. Prescrire Int 2006;15:11-2
63. Moeremans K, Annemans L, Morris J. Slow-release cytarabine (DepoCyte) is cost-effective compared with standard cytarabine for intrathecal treatment of patients with lymphomatous meningitis. Blood 2004;104(Suppl):80a (Abstract 267)